Citius Pharmaceuticals, Inc.

CTXR
$0.56 (+ $0.00 + 0.13%)
Last updated: 2026-06-10 19:01 UTC
CTXR Metrics
Exchange
🇺🇸 NASDAQ XNCM
Nasdaq Capital MarketUnited StatesAmerica/New_York
SectorHealthcare
IndustryBiotechnology
ISINUS17322U2078
CUSIP17322U207
Market Price0.56
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E RatioN/A
EPS-4.87
Market Cap$14.0M
Book Value4.5
Price to Book0.169
Beta1.51
52w High5.95
52w Low0.63
Next Earnings DateN/A

Citius Pharmaceuticals, Inc. trades under ticker CTXR on NASDAQ as a stock. Use this page to review stock price, share price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US17322U2078, CUSIP 17322U207. Also searched as Citius Pharmaceuticals.

Related researchCTXR stock priceCTXR share priceCitius Pharmaceuticals stockCitius Pharmaceuticals share price17322U207
About the Company
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of ARDS. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Price History